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Fibrates are known to induce peroxisome proliferation and
the expression of peroxisomal-oxidation enzymes. To analyze
fibrate-induced changes of complex metabolic networks, we
have compared the proteome of rat liver peroxisomes from con-
trol and bezafibrate-treated rats. Highly purified peroxisomes
were subfractionated, and the proteins of thematrix, peripheral,
and integral membrane subfractions thus obtained were ana-
lyzed by matrix-assisted laser desorption ionization time-of-
flight/time-of-flight mass spectrometry after labeling of tryptic
peptides with the iTRAQ reagent. By means of this quantitative
technique, we were able to identify 134 individual proteins, cov-
ering most of the known peroxisomal proteome. Ten predicted
new open reading frames were verified by cDNA cloning, and
seven of them could be localized to peroxisomes by immunocy-
tochemistry. Moreover, quantitative mass spectrometry sub-
stantiated the induction of most of the known peroxisome pro-
liferator-activated receptor -regulated peroxisomal proteins
upon treatment with bezafibrate, documenting the suitability of
the iTRAQprocedure in larger scale experiments. However, not
all proteins reacted to a similar extent but exerted a fibrate-
specific induction scheme showing the variability of peroxisome
proliferator-activated receptor-transmitted responses to specific
ligands. In view of our data, rat hepatic peroxisomes are appar-
ently not specialized to sequester very long chain fatty acids
(C22–C26) but rather metabolize preferentially long chain fatty
acids (C16–18).
Peroxisomes, often described asmultipurpose organelles, are
involved in numerous biochemical pathways of lipid and per-
oxide metabolism. The existence of more than 15 peroxisomal
inherited diseases like the Zellweger syndrome or X-linked
adrenoleukodystrophy, which are often lethal, emphasizes the
vital importance of these organelles (1–3). Cells are able to
remodel the protein composition of their peroxisomes and to
adjust the number of these organelles in response to physiolog-
ical or environmental stimuli to cope with themetabolic needs.
Consequently, peroxisomes are regarded as highly modular
organelles, with different protein composition depending on
the metabolic function or cell type. Fibrates, used as hypolipi-
demic drugs, induce both the proliferation of peroxisomes as
well as the-oxidation of fatty acids (4). These alterations of the
metabolic functions of peroxisomes are accompanied by
changes of proteins involved in the biogenesis of the organelles
as well as in enzymes for the breakdown of fatty acids (5, 6).
Several investigators in the past have used fibrate-induced per-
oxisome proliferation as a model to analyze selected aspects of
peroxisome biogenesis or lipid metabolism, using techniques
like Western blotting, enzyme assays, immunocytochemistry,
Northern blotting, or in situ hybridization (6–11). However,
complex rearrangements of the entire peroxisomal proteome
could not be analyzed with these techniques.
In this respect, mass spectrometry represents a straightfor-
ward alternative, particularly because of the development of
more sensitive analyzers and the introduction of isotope label-
ing reagents (12). Thus, it is now possible to characterize the
different physiological states of an organelle structure by top-
down quantitative mass spectrometry because of its ability to
identify hydrophobic polypeptides, like integral membrane
proteins (13–16), to investigate quantitative changes of individ-
ual proteins, even of low abundance, by the use of stable iso-
tope-labeled tags (17), and to record modulations of selected
pathways in response to exogenous stimuli. Last but not least, it
enables the identification of previously undetected proteins and
their integration into a cellular network as a basis for further
functional studies.
Because of their small proteome, peroxisomes represent a
model of comparably low complexity suitable to use quantita-
tive MS3 in a functional approach. By using this technique, we
have analyzed the peroxisomal proteome in response to fibrate
treatment with the aim to elucidate complex proteome rear-
rangements, to identify undetected proteins, and to define their
subcellular location and organelle-specific functions. In our
analysis we isolated peroxisomes from bezafibrate-treated and
control rats bymeans of density gradient centrifugation using a
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standardized procedure (18). To further increase the precision
of the analysis, isolated peroxisomeswere carefully subfraction-
ated into matrix and peripheral as well as integral membrane
protein fractions to enrich low abundant proteins. The proteins
were directly digested with trypsin and labeled with iTRAQ
reagent for quantitative liquid chromatography-MS/MS analy-
sis. Thus, we were able to identify 134 proteins, including 15
new predicted open reading frames. Ten of them could be
verified by cDNA cloning, and seven were shown to localize
at least partially to peroxisomes. The quantitative assess-
ment of protein abundance in response to the fibrate treat-
ment revealed no new fibrate-induced protein species. Con-
vincing evidence, however, is provided by the quite distinct
induction rates of long chain fatty acid synthetase and PMP70
in contrast to very long chain fatty acid synthetase and ALDP
and the finding that long chain fatty acids (C16–C18) rather
than very long chain fatty acids (C22–C26) are the primary
substrates of rat liver peroxisomes after fibrate treatment.
EXPERIMENTAL PROCEDURES
Maintenance and Bezafibrate Treatment of Rats—Female
Sprague-Dawley rats (200–300 g) were kept in accordancewith
the guidelines of the humane care and use of laboratory animals
at the Zentrale Versuchstieranlage, University of Heidelberg,
Germany. Each of 50 animals was fed for 10 days with 20 g of
Altromin 1324 (Altromin International, Lage, Germany) con-
taining 1mg/g bezafibrate (RocheDiagnostics), equaling a dose
of 75 mg/kg body weight. The control group of 70 animals
was fed with the same amount of untreated Altromin 1324.
After the 10-day treatment, the animals were starved overnight
and anesthetized with chloral hydrate. Subsequently, livers
were excised, weighed, andminced in ice-cold homogenization
buffer (250 mM sucrose, 5 mM MOPS, 1 mM EDTA, 0.1% etha-
nol, 2mM phenylmethylsulfonyl fluoride, 1mM dithiothreitol, 1
mM -aminocaproic acid, pH 7.2).
Isolation and Subfractionation of Peroxisomes—Homogeni-
zation of the tissue and subcellular fractionationwas performed
according to Vo¨lkl and Fahimi (18) with a few modifications
described by Weber and co-workers (19). Finally, purified per-
oxisomes were washed once with gradient buffer (5mMMOPS,
1 mM EDTA, 0.1% ethanol, 2 mM phenylmethylsulfonyl fluo-
ride, 1 mM dithiothreitol, 1 mM -aminocaproic acid, pH 7.2)
and stored at80 °C. For subfractionation intomatrix, periph-
eral, and integral membrane compartments, peroxisomes were
thawed and centrifuged at 30,000 g, resulting in supernatant
S1 and pellet P1. P1 was resuspended in TVBE buffer (1 mM
Na2CO3, 1 mM EDTA, 0.1% ethanol, 0.01% Triton X-100, pH
7.6), supplemented to 0.1% Triton and sonicated with two 15-s
pulses at 100 watts for quantitative membrane disruption.
Thereafter, a second centrifugation step at 100,000  g for 30
min, resulted in a first membrane pellet (P2) and supernatant
S2. To remove peripherally attached proteins, P2 was sus-
pended in 250mMKCl and centrifuged again at 100,000 g (S3
and P3). Subsequently, P3 was suspended in 100 mM Na2CO3
and kept on ice for 30 min. After a final centrifugation at
100,000  g, the supernatant (S4), containing mainly the core
protein urate oxidase (90%), was discarded, and the integral
membrane pellet (P4)waswashed and stored in gradient buffer.
For the matrix fraction, S1 and S2 were combined, concen-
trated with VivaSpin columns (MW 5000, Sartorius, Goettin-
gen, Germany), and dialyzed in gradient buffer. Supernatant S3
was concentrated and dialyzed in the same way to obtain a
fraction of peripherally attached membrane proteins.
iTRAQ Labeling and Liquid Chromatography-MS/MS—To
ensure that equal protein amounts were subjected to iTRAQ
labeling, first protein concentrations of the subfractions were
determined by the Bradford method. For a more precise com-
parison of protein amounts in themembrane fractions, aliquots
of all three subfractions were run on an SDS gel and stained
with Coomassie Blue. Thereafter, staining intensity of the pro-
tein pattern was compared by densitometric analysis of the gel
(Quantity One Software, Bio-Rad). Peroxisomal proteins (100
g per sample) were trypsin-digested (membrane pellets were
first solubilized in 0.8% RapiGest, Waters) and tagged with
iTRAQ reagents according to the protocol provided by the
manufacturer (Applied Biosystems). The iTRAQ-labeled pep-
tides were resolved in the first-dimensional liquid chromatog-
raphy with a polysulfoethyl A column. Peptides were eluted
with a linear gradient of 0–500 mM KCl in 20% acetonitrile, 10
mM KH2PO4, pH 2.9, over 25 min at a flow rate of 50 l/min.
Fractions were collected at 1-min intervals, dried, and redis-
solved in 30 l of 0.1% trifluoroacetic acid. For the second-
dimensional liquid chromatography, 10 l were injected into a
capillary C18 column (150 100 mm inner diameter. column)
at 500 nl/min and separated with a linearly increasing concen-
tration of acetonitrile from 5 to 50% in 30 min and to 100% in 5
min. The eluent was mixed with matrix (7 mg of -cyanohy-
droxycinnaminic acid in 1 ml of 50% acetronitrile, 0.1% triflu-
oroacetic acid, 10 mM dicitrate ammonium) delivered at a flow
rate of 1.5 ml/min and deposited off-line to the Applied Biosys-
tems metal target every 15 s for a total of 192 spots, and ana-
lyzed on an ABI 4700 proteomics analyzer. Peptide CID was
performed at 1 kV; the collision gas was nitrogen.MS/MS spec-
tra were collected from 5000 laser shots. The peptides with
signal to noise ratio above 50 at the MSmode were selected for
MS/MS experiment; amaximumof 30MS/MSwas allowed per
spot. The precursor mass window was 180 relative resolution
(at full width half-maximum). MS/MS spectra were searched
against the rat and mice data bases (Celera Discovery System,
CDS) using GPS Explorer (ABI) and Mascot (MatrixScience)
with trypsin specificity and fixed iTRAQmodifications at lysine
residue and the N termini of the peptides. Mass tolerance was
100 ppm for precursor ions and 0.5 Da for fragment ions; one
missed cleavage was allowed. For eachMS/MS spectrum, a sin-
gle peptide annotation with the highest Mascot score was
retrieved. CDS protein sequence redundancy was removed by
clustering the precursor protein sequences of the retrieved pep-
tides using the cluster algorithm Cd hit (20) at a sequence sim-
ilarity threshold of 90%. Subsequently, all peptides were
matched against the obtained protein clusters; those peptides
thatmatchedmore than one protein cluster represent common
sequences between proteins and were not considered for pro-
tein identification and quantification. For quantification, peak
areas for each iTRAQ signature peak were obtained and cor-
rected according to the manufacturer’s instruction to account
for the differences in isotopic overlap. To compensate for the
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possible variation in the starting amount between the samples,
the individual peak areas of each iTRAQ signature peak were
log2-transformed to obtain a normal distribution and then nor-
malized to the total peak area of this signature peak. Low sig-
nature peaks generally have larger variation, which may com-
promise the quantitative analysis of the proteins. Therefore, the
iTRAQ signature peaks lower than 2000 were removed from
quantitation. Within an MS experiment a Student’s t test was
used over bezafibrate versus control groups.
In the mass spectrometry, samples of peripheral and integral
membrane proteins were run in parallel to obtain quantitative
information on proteins retained at the membrane after car-
bonate stripping (data not shown). Becausemost of the proteins
detected in the peripheral fraction were found in the matrix as
well but specifically enriched proteins were not detected, the
data for these subgroups were combined in Table 4. The ratio
obtained for individual proteins identified in both groups was
used to calculate a conjoint value for the induction in both
subfractions to reduce data complexity. Themass spectrometry
of the peroxisomal matrix was done independently, in a double
experiment, and hence the quantitative measurements are
shown as autonomous data. As a threshold for proteins pre-
sented, we used the identification of at least three peptides with
the ion score of the highest peptide match 95% or two pep-
tides with the highest peptide match 99%. For completion,
some known peroxisomal proteins with identification rates
below the threshold (indicated in Table 4) were included in the
lists, because of the high probability of detection in a fraction of
isolated peroxisomes. Nevertheless, only proteins detected
with at least three peptides (peak area 2000) were considered
for quantification.
Immunoblotting of Selected Peroxisomal Proteins and
Enzyme Assays—Western blotting was performed according to
the semi-dry method using polyvinylidene difluoride mem-
branes (21). Antibodies used for the immunodetection of
selected proteins are of rabbit origin and were raised as pub-
lished previously (uricase, PMP70, catalase, L-bifunctional
enzyme, hydroxyacid oxidase, and acyl-CoA oxidase 1) or kind
gifts from T. Hashimoto, Shinshu University School of Medi-
cine, Nagano, Japan (long chain fatty acid CoA ligase 1, PMP22,
and Pex11), J. Adamski, GSF-Neuherberg, Germany (D-bi-
functional enzyme), and G. Dodt, University of Tuebingen,
Germany (Pex14). The polyclonal antibodies against GRP78/
BiP and PECI were purchased from BD Biosciences.
The activity of acyl-CoA oxidase 1 (ACOX1)was determined
according to Small et al. (22) and total -oxidation activities as
described by Lazarow and De Duve (4). Enzyme activities of
catalase, esterase, cytochrome c oxidase, and acid phosphatase
were performed as described previously (18).
Plasmids and Cloning of Expression Vectors for Newly Identi-
fied Peroxisomal Proteins—For the cloning of newly identified
potential peroxisomal proteins, total rat liver RNAwas isolated
using RNeasy mini kit (Qiagen, Hilden, Germany) and reverse-
transcribed into cDNA by SuperScript III reverse transcriptase
(Invitrogen). Primers spanning the whole predicted open read-
ing frame of the genes of interest were synthesized at MWG
(Mu¨nchen, Germany). PCR amplification of the target cDNAs
was performed using Pfx polymerase (Invitrogen), and the
amplicon was directly cloned into TOPO II vectors. After
sequencing of the inserts (GATC, Konstanz, Germany), the
open reading frames were isolated and ligated into pCMV-Tag
vectors (Stratagene, Amsterdam, The Netherlands) for genera-
tion of fusions with the Myc epitope. For expression of Myc
fusion proteins in mammalian cell lines, the coding regions
were under control of the cytomegalovirus promoter. Except
for protein sequences with predicted PTS1 signals at the C ter-
minus where only N-terminal cDNA versions were con-
structed, both C- and N-terminally tagged versions were gen-
erated (see Table 1). For the analysis of wild-type protein
variants, open reading frames of XP_237252.1 (ACBD5.2) and
PMP52 were cloned into pCDNA3.1 vectors. In the case of
XP_237252.1 (ACBD5) the 5-end of the cDNA was deter-
mined using the GeneRacer RACE-PCR kit (Invitrogen). For
cotransfection experiments, plasmid pDsRed (Clontech) or
pGHL252 were used to visualize transgenic cells. The plasmid
pGHL252 contains the sequence encoding a fusion protein
(RFP-PTS1) of the red fluorescent protein (from pDsRed) with
a peroxisomal targeting signal SKL under control of themurine
ROSA26 promoter as well as an expression cassette for selec-
tion of bleomycin in prokaryotic and eukaryotic cells.
Cell Culture and Cell Lines—Chinese hamster ovary (CHO)
cells and CHO-derived cells were maintained in Ham’s F-12
medium supplemented with 10% fetal calf serum (PAA, Co¨lbe,
Germany) in a fully humidified incubator at a temperature of
TABLE 1
Plasmid constructs used for microscopic investigations
Protein name Abbreviationused in text
Protein accession
number
GenBankTM accession
number of cDNA
Wild
type
N-terminal
tag
C-terminal
tag
Acyl-CoA dehydrogenase family member 11 Q80XL6 XM_236582  Myc 
3,2-Enoyl-CoA isomerase NP_001009275 BC088178.1  Myc 
Zinc-binding alcohol dehydrogenase domain
containing 2
Zn-ADH XP_214526 XM_001060611  Myc 
Mosc domain containing protein 2 MOSC2 O88994 AF095741.1  Myc Myc
Trypsin domain containing 1 Tysnd1 XP_345107.1 XM_001056113.1  Myc 
PMP52 PMP52 NP_001013918 NM_001013896  Myc Myc
Short chain dehydrogenase 7b Dhrs7b XP_213317.1 BC086453.1  Myc Myc
Dhrs7b.2 EF445633 Myc Myc
Acyl-CoA-binding protein ACBD5 ACBD5.1 XP_237252.1 EF026991  Myc Myc
ACBD5.2 EF026992 Myc Myc
Potential dienelactone hydrolase NP_001008770.1 BC088459.1  Myc Myc
Lactamase, 2 NP_663356 NM_001024247.1  Myc 
Ezrin-radixin-moesin-binding phosphoprotein EBP 50 Q9JJ19 AF154336.1  Myc 
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37 °C and an atmosphere of 5% CO2 in air. For visualization of
peroxisomes in living cells, CHO cells were transfected with a
mixture of plasmid pVgRXR (Invitrogen) and of plasmid
pGHL97 (23) that contains an expression cassette for a GFP-
PTS1 fusion protein under control of the murine phosphoglyc-
erate kinase promoter. Cell clones were analyzed by fluores-
cence microscopy for expression of the GFP-PTS1 fusion
protein, and positive clones were isolated for further analysis.
One of the resulting cell clones with homogeneous expression
of the GFP-PTS1 was named BGL69 andwas used in this study.
Subcellular Localization of Epitope-tagged Proteins—For
colocalization studies of epitope-tagged proteins with peroxi-
somes, expression vectors were transiently transfected into
BGL69 cells cultured on glass coverslips using the Gene Porter
system (Peqlab, Erlangen, Germany) according to themanufac-
turer’s recommendations. After transfection, coverslips were
washed with PBS and then fixed at room temperature in 4%
freshly depolymerized paraformaldehyde in 0.15 M HEPES, pH
7.4, for 15min. Cells were washed and permeabilized with 0.2%
TritonX-100 and 0.2%Tween 20 in PBS. To reduce nonspecific
binding of antibodies, cells were blocked for 30 min with Roti-
Block (Roth, Karlsruhe, Germany) in PBS. Roti-Block was also
used for dilution of specific primary andCy3-labeled secondary
antibodies. Cells were incubated with monoclonal primary
antibodies against the Myc epitope (9E10, kindly provided by
M. Schrader, University of Marburg, Germany) for 1 h. After
washing the coverslips three times for 5 min, they were incu-
bated with the Cy3-labeled goat anti-mouse antibodies
(Dianova, Hamburg, Germany) for 1 h. Control stainings were
performed according to the same protocol except that the pri-
mary antibodies were omitted. After a final washing, the cover-
slips were mounted with 50% glycerol in PBS containing 1.5%
(w/v) n-propyl gallate as an antifade. For visualization of mito-
chondria, living CHO cells were incubated in Ham’s F-12
medium supplemented with 0.5 MMitoTracker Red (Invitro-
gen) for 30 min followed by an incubation in regular medium
for 15 min. Cells were fixed and propagated for immunocyto-
chemistry as described. For costaining of the Myc epitope in
Mitotracker-labeled cells, the monoclonal anti-Myc antibodies
were visualized using a Cy2-labeled goat anti-mouse antiserum
(Dianova, Hamburg, Germany). Visualization of the endoplas-
mic reticulum with Concanavalin A was performed as
described recently (23).
Light microscopic analysis was carried out on a Leica DMRE
fluorescence microscope (Leica, Wetzlar, Germany) with
standard filters for detection of fluorescein isothiocyanate and
Cy3. Digital images were acquired using a DXM1200F digital
camera system with the Nikon ACT-1 software.
RESULTS
Fibrates are known to induce hepatomegaly, to stimulate
peroxisome proliferation, and to induce the enzymes involved
in the -oxidation of fatty acids (6). Accordingly, the bezafi-
brate treatment of animals was found to cause an increase in
liver weight of 18.8% compared with untreated control animals
(9.24 1.06 versus 7.78 0.64, p 0.001). Amore pronounced
effect of the drug treatmentwas observed at the organellar level.
Total peroxisomal protein increased from 26.5 to 102.4 g/g
liver, reflecting a 3.9-fold augmentation. Because this ratio was
more or less consistent in all peroxisomal subfractions (matrix,
4.2, integralmembrane fraction 3.3; peripheralmembrane frac-
tion, 3.7), peroxisomes were increased primarily in their num-
ber and to a lesser extent in size.
In Table 2, the properties of peroxisomes isolated in up to 10
experiments are summarized. According to the values concern-
ing catalase and -oxidation activities, the peroxisomal frac-
tions obtained are highly enriched (purity of 95%), with an
average contamination by mitochondria and by endoplasmic
reticulum of 2%, and hence are expected to meet the require-
ments for proteome analysis. To evaluate also the purity and
contamination of peroxisomes isolated from bezafibrate-
treated animals, we used the marker enzymes cytochrome c
oxidase (mitochondria), esterase (endoplasmic reticulum), and
acid phosphatase (lysosomes) to compare the former with
“control peroxisomes.” Because of the increase in peroxisome
number in response to the treatment, most contaminating
organelles decreased. In detail, the activities of cytochrome c
oxidasewere reduced by the factor of 3.4 and of esterase by 1.92,
whereas that of acid phosphatase was augmented by the factor
of 2.3 (Table 3), although no lysosomal proteins could be iden-
tified in the MS analysis.
To improve the precision of ourMS analysis, isolated peroxi-
somes were subfractionated into so-called matrix, peripheral,
and integralmembrane fractions prior toMS/MS. Because per-
oxisomes exhibit a quite unique ratio of membrane to matrix
(usually 1:10) and, moreover, are characterized by a portion of
“poorly soluble” matrix proteins, which do not easily separate
from the membrane (24), we had to adapt our subfractionation
protocol to obtain a membrane preparation as pure as possible.
For this purpose, we first disrupted the organelles by freezing
and thawing in the presence of 0.075% Triton X-100, followed
by sonication in 0.1% Triton X-100. Using this procedure, the
TABLE 2
Properties of the peroxisome fraction (PO) purified from livers of untreated rats
Values given aremean values S.D. Relative specific activity (RSA), units/mg PO protein (units/mg liver protein)1. Purity/contamination of purified POwas calculated
according the formula given by Leighton et al. (7): purity	 p RSA, where p is percentage of total liver protein contributed by PO (2.53).
Enzyme No. ofexp. Units/g liver
Units/mg liver
protein Recovery in PO
Relative specific
activity Specific activity Purity/contamination
mg/g liver % total liver Units/mg PO protein %
Protein 10 265.36 81.84 0.28 0.08
Catalase 10 53.86 11.34 202.96 103 9.96 1.92 37.67 4.28 7.65 95.31
Lipid -oxidation 4 0.951 0.255 3.58 103 11.18 3.25 36.32 5.09 0.130 91.89
-Glucuronidase 4 10.12 1.56 38.14 103 0.014 0.01 0.069 0.056 0.003 0.139
Esterase 6 326.15 65.46 1.229 0.014 0.01 0.093 0.07 0.114 1.99
Cytochrome c oxidase 8 33.10 9.45 124.74 103 0.018 0.02 0.09 0.05 0.011 1.82
Lactate dehydrogenase 2 448.15 6.98 1.689 0.06 0.294 0.497
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matrix fraction was indeed enriched with the poorly soluble
matrix proteins, e.g. the bifunctional enzymes (supplemental
Fig. S1a), which was not possible with lower Triton X-100 con-
centrations. Yet, the Triton treatment also solubilized the inte-
gral membrane proteins to a minor extent (supplemental Fig.
S1b), which was accepted to avoid contamination of the mem-
brane fraction by matrix proteins. High salt KCl treatment is
typically used for extraction of peripheral membrane proteins.
However, because a complete clearance of poorly soluble
matrix proteins from the membranes was not possible keeping
detergent concentrations at an acceptable level, a distinct con-
tamination ofmatrix proteins in the peripheralmembrane frac-
tion could not be avoided (supplemental Fig. S1c). In a last frac-
tionation step the high abundant protein uricase was released
from the membranes by washing with 100 mM carbonate.
Concerning total protein amounts, we obtained the following
distribution: matrix control, 12.6 mg; peripheral membranes
control, 2 mg, integral membranes control, 1 mg; matrix beza-
fibrate, 46.3 mg; peripheral membranes bezafibrate, 5.6 mg;
integral membranes bezafibrate, 3 mg.
Identification of Proteins Using MS/MS—After combining
the analysis of all three peroxisomal subfractions, we were able
to identify 134 different proteins or predicted peptide
sequences (Table 4) matched from at least three peptides with
an identification score of 95% or two peptides with 99%.
Among these peptides were 57 bona fide peroxisomal proteins
above that threshold as well as 18 microsomal, 16 mitochon-
drial, 15 cytosolic, 12 proteins of other sources, and 15 unde-
fined peptide sequences (Table 4). With respect to the peroxi-
somal proteins, the mass spectrometric analysis reflected the
biological function of peroxisomes in rat liver. The enzymes of
lipid metabolism and the H2O2-degrading catalase were most
prominent in the peroxisomal matrix subfraction judged from
the ion scores and the number of peptides identified.High iden-
tification rates were also obtained for isocitrate dehydrogenase,
strengthening the hypothesis of its role in generation of
NADPH that is required for the breakdown of polyunsaturated
fatty acids. Interestingly, we could verify the localization of only
one enzyme of cholesterol biosynthesis supposed to be in per-
oxisomes, the hydroxymethylglutaryl-CoA synthase (Table 4).
Thismay be an indication that thewhole pathway of cholesterol
synthesis is not localized in peroxisomes (25) and that the per-
oxisomal enzyme serves other tasks.
The mitochondrial glutathione S-transferase 1, suggested
to be a peroxisomalmatrix protein (26), was one of the proteins
detected with highest identification rates (peptide count 13,
highest confidence interval per peptide 100%). Therefore, in
addition to the enzymes scavenging reactive oxygen species like
catalase andCu,Zn superoxide dismutase (SOD1), peroxisomes
contain high amounts of a third enzyme to protect the organelle
from lipid peroxidation.
Within the peripheralmembrane protein fraction,we did not
find any peroxisomal proteins thatwere specifically enriched by
bezafibrate. The membrane proteins were predominantly
found in the carbonate-stripped protein fraction, including
exclusively all newly identified proteins with predicted mem-
brane-spanning helices according to TMHMM (Table 5). The
major proteins found were the long chain fatty acid CoA ligase
1 (LACS1) and PMP70, both assigned to the function of fatty
acid import (Table 4). According to the total ion score, very
long chain acyl-CoA synthetase and ALDP are only present in
low amounts in liver peroxisomes. In addition to proteins
involved in lipid metabolism or transport of metabolites, we
also detected nine peroxins. Pex2, -5, and -16, which were
found but did not reach the identification threshold, were
included in Table 4, because they are well characterized perox-
isomal proteins, likely to be found in a peroxisomal protein
sample.
We also detected proteins from other subcellular compart-
ments in our proteome analysis. Their relative abundance var-
ied depending on the original compartment. Mitochondrial
proteins identified here generally belong to the respiratory
chain or urea cycle and represent themost abundant proteins of
this organelle. In contrast, microsomal and cytosolic proteins
appeared to be part of distinct functional groups. Many of the
microsomal proteins identified were chaperones and chaper-
one-related proteins. This selection of proteins suggests that
they belong to a specialized microsomal subcompartment and
were not just present because of a generalizedmicrosomal con-
tamination. Other proteins like the fatty aldehyde dehydrogen-
ase, cytochrome b5, and the NADH-cytochrome b5 reductase
(27–29) have already been described in peroxisomes and there-
fore may not be contaminants but proteins with a genuine par-
tial peroxisomal localization.
The cytosolic proteins identified primarily belong to various
pathways of energy metabolism and thus seem to be contami-
nants. However, the ezrin-radixin-moesin binding protein
EBP50 possesses a PTS1 sequence at its C terminus implying a
potential peroxisomal localization, which indeed could be con-
firmed by experiments described below.
Validation of Quantitative iTRAQ Data by Immunoblotting—
The data acquired by iTRAQ analysis were validated by immu-
noblotting of selected peroxisomal proteins (Fig. 1). To perform
a correlation analysis between both techniques, the intensities
of bands were quantified using theQuantityOne software (Bio-
Rad). A correlation of all values acquired by both techniques
resulted in a correlation coefficient of 0.62 (Excel, Microsoft).
The overt inconsistencies between the iTRAQ and densitome-
try values may be caused by inaccuracies due to extremely low
protein abundance in the sample. Thus, we excluded values
from faint immunobands and/or iTRAQ data based on less
than three peptides from the correlation analysis. After omit-
ting these values the correlation coefficient rose to a value of
0.69. As a consequence, the semiquantitative evaluation of the
TABLE 3
Marker enzymes activities in isolated peroxisomes of bezafibrate-
treated and control animals
Enzyme Control Bezafibrate
Units/mg Units/mg
Catalase 8.5 8.0
ACOX 1 (C18) 24.13 24.83
ACOX 1 (C24) 1.13 0.30
-Oxidation (C18) 16.98 (milliunits/mg) 45.45 (milliunits/mg)
-Oxidation (C24) 0.30 (milliunits/mg) 0.22 (milliunits/mg)
Unspecific esterase 0.140 0.073
Acidic phosphatase 0.096 0.223
Cytochrome c oxidase 0.017 0.005
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TABLE 4
List of protein identifications
A total of 134 proteins was identified with a threshold of three matching peptides, 95% probability for the peptide with the highest identification score or two peptide
matches with a probability 99%. If a protein was found in the matrix and membrane fractions, the higher identification score was included into the list. iTRAQ values
showing significant alterations according to a Student’s t test are highlighted with the following color code: proteins up-regulated are shown in green and down-regulated
proteins are highlighted in orange. Darker colors indicate changes of more than 100%. Proteins unaffected by the treatment are shown in yellow.
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TABLE 4—continued
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bezafibrate treatment shown in Table 4 was based only on
iTRAQ data of peroxisomal subfractions, in which proteins
were detected by at least three peptides with a peak area2000.
Nevertheless, some inconsistencies were also evident for pro-
teins, which were clearly detected by both techniques. For
example, catalase is reduced in thematrix fraction according to
the iTRAQdata, although it remainedmore or less stable in the
immunoblots. Similarly, hydroxyacid oxidase is down-regu-
lated in the iTRAQ analysis but induced according to the bands
of the immunoblots. Both proteins were identified by more
than 15 peptides, which means that more than 30 individual
quantifications contributed to the iTRAQ value. To gain value
of these data we performed a Student’s t test in which only the
data with significant variation was considered for subsequent
interpretation. Otherwise, immunoblot quantification is based
on the premise that exactly the same protein amounts have
been loaded onto the gel. However, inaccuracies in the meas-
urement of the protein concentration will lead to errors in the
quantification of bands. In particular, this leads to problems in
highly modulated protein samples like peroxisomes before and
after fibrate treatment, because no housekeeping proteins can
be used for validation. These problems can be avoided in the
iTRAQ analysis, because protein amounts can be compensated
virtually by the analysis software. Despite these drawbacks clear
up- or down-regulations were detected in parallel as docu-
mented by the high induction rates of Pex11, L-PBE, or PMP70
TABLE 4—continued
TABLE 5
Molecular parameters of newly identified proteins
GenBankTM accession
number Name
PTS1 according to PTS1
predictor analysis software
No. of predicted
membrane helices in
TMHMM (GRAVY)
pI Mr
Q80XL6 Acyl-CoA dehydrogenase family member 11 LQDQARQLKARM 0 (0.210) 8.40 87.37
Yes, score 11.5
NP_001009275.1 3,2-Enoyl-CoA isomerase ALRNFLSRKAKI 0 (0.332) 8.57 33.69
Yes, score 10.9
XP_214526 Zinc-binding alcohol dehydrogenase
domain containing 2
VVELPHPVSSKL 0 (0.143) 7.63 40.48
Yes, score 2.7
O88994 Mosc domain-containing protein 2 LRVGDPVYRMVD 1 (0.210) 8.95 38.25
No, score2.7
XP_345107.1 Trypsin domain-containing 1(Tysnd1) QRPLPEAPRSKL 0 (0.165) 6.50 58.99
Yes, score 13.8
NP_001013918 PMP52 TVVTPELPIDFS 5 (0.178) 9.58 52.36
No, score79.6
Q6I7R3 Isochorismatase domain-containing protein 1 ASAPESGLLSKV 1 (0.322) 6.96 32.00
Yes, score 3.0
XP_213317.1 Short chain dehydrogenase 7b SRARKERKSKNS 1 (0.072) 9.61 35.34
No, score68.5
XP_23.7252.1 Acyl-CoA-binding protein ACBD5 HLYYQRRRRKLN 1 (0.651) 6.00 72.14
No, score55.3
NP_001008770.1 Potential dienelactone hydrolase RRNLIEWLNKYI 0 (0.268) 6.24 27.90
No, score27.9
NP_663356 Lactamase 2 TTTPVKKWKAVL 0 (0.302) 5.89 32.75
TwZ, score3.9
Q9JJ19 EBP50 DWSKKNELFSNL 0 (0.774) 5.70 38.83
Yes, score 4.8
Q8VDX6 Transmembrane protein 5 ILESSFFINNKV 1 (0.355) 8.89 51.39
No, score26.56
Q6AY30 Probable saccharopine dehydrogenase IQFSVISSSEVV 1 (0.038) 9.02 47.10
No, score87.54
AAH88229.1 MOSC N-terminal -barrel domain (LOC690745) TIKVGDPVYLLS 0 (0308) 6.13 21.67
No, score52.90
Q8CBY1 Sterile motif domain-containing protein 4A ALGDGVDRTSTI 0 (0.469) 8.61 69.04
No, score57.68
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found in both techniques. As a consequence, we focused the
data interpretation on the clearly regulated proteins involved in
the pathways of -oxidation of fatty acids.
Bezafibrate-induced Changes in Protein Abundance Meas-
ured by iTRAQ Quantification—Treatment of rodents with
bezafibrate causes a general augmentation of the peroxisomal
compartment as well as a remodeling of the enzymatic pattern
of the organelles, leading to an enhanced capacity to sequester
long and very long chain fatty acids in the liver. This process is
reflected by the differential expression of peroxisomal proteins
in our study.
The iTRAQ values imply that a number of peroxins were
induced in the liver of bezafibrate-treated rats compared with
control animals. Highest induction rates were observed for
Pex11, a peroxin implicated in the process of membrane fis-
sion (Table 4).
As expected, we also observed a significant increase in puta-
tive enzymes of -oxidation of straight long chain fatty acids
(C16–C18), e.g. the L-bifunctional enzyme (L-PBE) or the 3-ke-
toacyl-CoA thiolase after bezafibrate treatment. In contrast,
the corresponding enzymes of the -oxidation of very long
straight chain fatty acids, the D-bifunctional enzyme (D-PBE),
ALDP, the very long chain acyl-CoA synthetase, and the thio-
lase harboring SCPX were only induced to a lower extent or
even down-regulated. This is in line with the low -oxidation
rates found for lignoceroyl-CoA comparedwith palmitoyl-CoA
in both the induced andun-induced state (Table 3). Apparently,
MS allows for the detection of changes in the regulation of
entire metabolic pathways. With respect to the total mass of
peroxisomal proteins, ACOX1 was not or only slightly induced
but remained stable after fibrate treatment. Similar results were
shown for ACOX2 and ACOX3 (Table 4). Furthermore, the
enzyme activities of ACOX1 for the oxidation of palmitoyl-
CoA were also comparable in bezafibrate-treated and control
animals (24.83 versus 24.13 units/mg protein). The remaining
peroxisomal enzymes involved in lipid metabolism increased
upon fibrate treatment further substantiating that liver peroxi-
somes remodel their enzymatic composition predominantly, to
effectively sequester unbranched long chain fatty acids.
Enzymes for the entire pathway, including potential transport-
ers such as PMP70, proteins for storage of fatty acids like fatty
acid-binding protein p14, the peroxisomal acyl-CoA thioester-
ase 4 (ACOT4), or different carnitine acyltransferases involved
in transfer of shortened fatty acyl-CoAs to mitochondria, also
were all increased by bezafibrate treatment (Table 4).
Localization of Newly Identified Peroxisomal Matrix Pro-
teins—To substantiate the identification of newly identified
peroxisomal proteins, we focused on the analysis of proteins
fused with the Myc or FLAG epitope. Epitope-tagged pro-
teins were expressed in CHO cells (BGL69) with constitutive
expression of a GFP-PTS1 fusion protein for visualization in
peroxisomes. For proteins with a predicted PTS1 sequence
(Table 5), we investigated only protein variants with an
N-terminal tag. For all other proteins, N- as well as C-termi-
nal fusions with epitope tags were constructed to preserve
possible targeting information located at the termini of the
proteins. We found that EBP50 (Q9JJ19), a presumed cyto-
solic protein with a PTS1 signal in its peptide sequence, was
localized almost exclusively to peroxisomes when expressed
in BGL69 cells in moderate amounts (see Fig. 2, A–C) sug-
FIGURE 1. Immunoblots of selected proteins compared with iTRAQ ratios acquired by MS. For the validation of the quantitative MS data, iTRAQ ratios
(bezafibrate/control) are comparedwith band intensities of the immunoblots shown. Equal protein amounts of each peroxisomal subfractionwere loaded on
thegels, and after transfer to polyvinylidenedifluoridemembranes, individual proteinsweredetectedby specific antibodies as describedunder “Experimental
Procedures.” For densitometry, Quantity One software (Bio-Rad) was used. The abbreviations used are as follows: C, control; B, bezafibrate; Uox, uricase; LACS
1, long chain fatty acid CoA ligase 1; Cat, catalase; D-PBE, L-bifunctional enzyme; HAOx, hydroxyacid oxidase; D-PBE, D-bifunctional enzyme; ACOX1-A, -B, -C,
acyl-CoA oxidase 1, band 1, 2, and 3; id, identified.
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gesting that this protein possesses a functional PTS1. How-
ever, when expressed at higher levels, it was also found in the
cytosol (not shown), where it has been described originally as
a scaffolding protein attached to proteins of the ezrin-ra-
dixin-moesin family (30). Similarly, trypsin domain contain-
ing 1 (XP_345107.1, Tysnd1), the acyl-CoA dehydrogenase
family member 11 (Q80XL6), the 3,2-enoyl-CoA isomer-
ase (NP_001009275), and the zinc-binding alcohol dehydro-
genase domain containing 2 (XP_214526, Zn-ADH) were all
targeted to peroxisomes, when fused with a Myc epitope at
their N terminus (see Fig. 2, D–G). However, not all identi-
fied proteins with a PTS1 in their predicted peptide sequence
were localized to peroxisomes. The potential lactamase 2
(NP_663356) ending with the amino acids AVL at its C ter-
minus was not localized to a specific subcellular structure
upon expression in BGL69 cells, demonstrating that a PTS1
analog-targeting sequence is not always a guarantee for per-
oxisomal import (Fig. 2H).
Localization of Newly Identified Peroxisomal Membrane
Proteins—For newly identified proteins without an obvious
peroxisomal targeting sequence, e.g. theMosc domain contain-
ing protein 2, the subcellular localization was dependent on the
position of the epitope tag. The Mosc domain containing pro-
tein 2 (O88994) was mostly localized to peroxisomes when
fused with a C-terminal Myc tag (Fig. 3, A–C). However, when
the Myc epitope was fused to the N terminus of the protein,
most of theMyc immunoreactivity did not colocalize with per-
oxisomes (Fig. 3,D andE). Instead, the fusion proteinwas local-
ized tomitochondria, demonstrated by overlap of the immuno-
labeling with a mitochondrial marker shown in Fig. 3F. This is
in line with a predicted mitochondrial targeting sequence from
amino acids 1–35 as described in SwissProt. Because peroxiso-
mal membrane protein targeting sequences are highly variable,
it can only be speculated that the N-terminal tag disturbs the
targeting signal; however, a couple ofmembrane protein target-
ing sequences localize at least in part to the N terminus (31).
The subcellular localization of the short chain dehydrogen-
ase 7b (Q8VID1, Dhrs7b.1) was altered by its level of expres-
sion. When expressed at low levels, judged from the fluores-
cence intensity of the immunostaining, an N-myc-Dhrs7b.1
fusion was localized mostly to peroxisomes (Fig. 3, G and H).
Upon higher expression, however, most of the Myc immuno-
staining did not colocalize with GFP-PTS1 as the marker of
peroxisomes (not shown). A Dhrs7b fusion with the Myc
epitope at its C terminus did not localize to peroxisomes when
expressed in CHO cells (not shown).We also identified a splice
FIGURE 2. Newly identified proteins are localized to peroxisomes. Plas-
mids for expression ofMyc-tagged proteins were transiently transfected into
BGL69 cells that already express aGFP-PTS1 fusion protein for visualization of
peroxisomes (green signal in A). The Myc epitope was visualized immunocy-
tochemically (red signal in B). Colocalization of the Myc epitope with GFP-
PTS1 in overlays of images A and B is indicated by yellow signals (C). Cells in
A–Cwere transfected with a plasmid for expression of a N-myc-EBP50 fusion
protein.D–I,only theoverlays of images forGFP (green) and the localizationof
the following proteins (red) are shown. D, N-myc-Tysnd1; E, N-myc-Zn ADH;
F, N-myc-acyl-CoA dehydrogenase family member 11, G, N-myc-3,2-enoyl
CoA isomerase; H, N-myc-lactamase 2; and I, C-myc-ACBD5.1. Note the
almost complete colocalizationof proteinswith theperoxisomalmarkerGFP-
PTS1 except for image H. As shown for the gene product of lactamase 2 (H),
a PTS1 signal sequence does not guarantee a peroxisomal localization; how-
ever, the existence of splice variants, which are targeted to peroxisomes via
this PTS1, cannot be excluded. All images show the same magnification; the
bar in I represents 20 m.
FIGURE 3. Localization of proteins can vary with the position of the
epitope tag and the level of expression. Plasmids for expression of Myc-
tagged proteins were transiently transfected into CHO cells (F) or into BGL69
cells (all except F) with GFP-labeled peroxisomes (green signal in A). The Myc
epitope was visualized immunocytochemically (red signal in B–E and G–I or
green signal in F). A colocalizationof thegreen and red signals in overlays (C, E,
F, H, and I) of corresponding images is indicated by yellow signals. Cells in A–C
were transfectedwith a plasmid for expression of a C-myc-Mosc domain con-
tainingprotein 2 fusion.D–F, localizationof aN-mycMoscdomain containing
protein 2 fusion is shown. F, mitochondria of CHO cells were labeled in red,
and the Myc epitope was labeled in green. Note the complete overlap of the
signals. G–I, cells were transfected with plasmids for expression of an N-myc-
Dhrs7b fusion proteins.G andH show the initially published versionDhrs7b.1
fused to an N-terminal Myc tag; I represents the splice variant N-myc-
Dhrs7b.2, which colocalizeswith a concanavalin A staining (red) used tomark
the endoplasmic reticulum. All images show the samemagnification; the bar
in I represents 20 m.
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variant of the short chain dehydrogenase 7b (Dhrs7b.2, acces-
sion number EF445633). AnN-myc-Dhrs7b.2 fusion was local-
ized to the endoplasmic reticulumshownby colocalizationwith
concanavalin A (Fig. 3I) as predicted by the software PSORTII.
Expression of the N-myc-Dhrs7b.2-fusion induced a reorgani-
zation of the endoplasmic reticulum demonstrated by the aber-
rant concanavalin A staining pattern with a focal concentration
of the staining in several areas of N-myc-Dhrs7b.2-expressing
cells (Fig. 3I).
Among the new peroxisomal membrane proteins, we have
also identified proteins that caused alterations of the peroxiso-
mal morphology when expressed in BGL69 cells. A C-termi-
nally Myc-tagged version of the PMP52 (NP_001013918) was
colocalized with GFP-PTS1, indicating its association with per-
oxisomes (Fig. 4, A–C). However, as a result of the PMP52
expression, the number of peroxisomes was dramatically
reduced, and a significant portion of the GFP-PTS1 was local-
ized in the cytoplasm, indicating that its import was impaired.
The same result was obtained upon expression of PMP52 bear-
ing a N-terminal Myc tag (not shown). To exclude that the
alterations of peroxisomal import andmorphology were attrib-
uted to expression of artificial fusion proteins, we have also
analyzed BGL69 cells overexpressing the wild-type PMP52. An
expression vector for PMP52was cotransfectedwith pGHL252,
a vector for a RFP-PTS1 fusion protein, to visualize transfected
cells (Fig. 4, D–F). Indeed, the latter showed the same alter-
ations with a reduced number of peroxisomes and an impaired
import of GFP-PTS1 suggesting that low expression rates are
crucial for its physiological function. To quantify the frequency
of the PMP52-induced phenotype, we compared peroxisome
morphology and the localization of the GFP-PTS1 in BGL69
cells after cotransfection with the RFP-PTS1 and the PMP52
expression vector with that of BGL69 cells transfected with the
RFP-PTS1 vector alone. Analysis of 100 RFP-PTS1 transgenic
cells showed alterations of peroxisome morphology and cyto-
plasmic GFP localization in 89% of transgenic cells after
cotransfection, and only in 3% of transgenic cells of the controls
after transfection of the RFP-PTS1 alone. This observation
indicates that the alteration of the peroxisomal compartment
was indeed because of expression of wild-type PMP52.
By 5 rapid amplification of cDNA ends-PCR, we cloned two
splice variants of the acyl-CoA-binding proteinACBD5, named
ACBD5.1 (EF026991), lacking exon 1, and ACBD5.2
(EF026992). A slightly different effect on peroxisomemorphol-
ogy was observed upon expression of both variants of ACBD5.
ACBD5.2 tagged with an N-terminal Myc epitope caused a
tubular elongation of peroxisomes in BGL69 cells. The GFP-
PTS1 colocalized with the tubular Myc immunolabeling but
was mostly concentrated in dot-like beads on a string (Fig. 4,
G–I). Again, the same result was obtained by expression of
ACBD5.2 tagged with a C-terminal Myc epitope (not shown).
Furthermore, the transient expression of the wild-type
ACBD5.2 cotransfected with a DsRed expression vector for
visualization of transfected cells also caused the same pheno-
type (Fig. 4, J–L), suggesting an interferencewith the physiolog-
ical fission process. The ACBD5.1 was also localized to peroxi-
somes (Fig. 2I). We observed an induction of rod-like
peroxisomes in a fraction of ACBD5.1-expressing cells (not
shown), but the phenotype was much less pronounced com-
pared with that caused by ACBD5.2 overexpression.
DISCUSSION
The objective of this study was to characterize the proteome
of rat liver peroxisomes and to register regulative changes in the
peroxisomal protein pattern after treatment of rats with the
hypolipidemic drug bezafibrate. We chose this system to iden-
tify previously undescribed proteins, to link selected data from
the literature to an experiment at the organellar proteome level
to validate this quantitative approach, and to obtain a more
complex view of the alterations induced by hypolipidemic
drugs. Although proteomic profiling cannot replace metabolic
studies and detailed functional analyses, it can be a hypotheses-
generating instrument, giving rise to new cell biological ideas by
carefully interpreting the large amounts of data.
Quantitative Mass Spectrometry—For most peroxisomal
proteins, the iTRAQ analysis revealed that their abundance
FIGURE 4. Overexpression of newly identified peroxisomal membrane
proteins affects peroxisome morphology and import of peroxisomal
proteins. BGL69 cells with GFP-labeled peroxisomes (green in A, D, G, and J)
were transfected with plasmid for expression of the following proteins. A–C,
C-myc-PMP52; D–F, PMP52 and DsRed; G–I, N-myc ACBD5.2; or J–L, ACBD5.2
and DsRed. TheMyc epitopes (B and H) and the DsRed (E and K) are shown in
red. Overlays of corresponding images are shown in C, F, I, and L. Note the
reduced number of PMP52-positive peroxisomes (arrowhead in A–C) and the
cytoplasmic localization of GFP-PTS1 in transfected cells (C and D). Note also
the appearance of elongated N-myc-ACBD5.2-positive peroxisomes (arrow-
heads in insets of G and H) as well as of similar structures in cells transfected
with aplasmid for expressionofACBD5.2 (inset in J). All images showthe same
magnification; the bar in L represents 20 m.
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remained more or less constant in both control and fibrate-
treated animals if referred to the total amount of peroxisomal
protein. In relation to the total mass of liver protein, however,
peroxisome proliferation leads to an increased expression of
most peroxisomal proteins concomitant with corresponding
changes at the transcriptional level (32–35). However, the
iTRAQ quantification values also indicated specific alterations
of protein induction, when calculated per peroxisomal protein.
Although peroxins responsible for the import of matrix and
membrane proteins (Pex3, see Ref. 36) were both moderately
elevated (1.3–1.4 times), higher rates were found for Pex16
(1.75 times) and Pex11 (2.6 times), involved in early perox-
isome membrane assembly (37, 38) and peroxisome prolifera-
tion, respectively (39).
Modulations in the content of peroxisomal enzymes com-
monly imply a shift in their ability to sequester specific fatty
acid substrates (40). This notion is substantiated by the high
induction rates of the high abundant proteins L-PBE, the
3-ketoacyl-CoA thiolase, and the potential fatty acid trans-
porter PMP70 and the low to moderate ones of D-PBE,
ALDP, and the very long chain acyl-CoA synthetase (Table
4). As the D-PBE promoter bears a clear PPAR-response
element, these finding may appear contradictory. Yet as is
repeatedly reported, the D-PBE is only less induced com-
pared with L-PBE (see Ref. 41 for review), which may reflect
a more modular response of the D-PBE to different PPAR
ligands. Using a knock-out mouse model, Baes et al. (42)
elegantly showed that only the D-PBE takes part in the oxi-
dation of very long chain fatty acids (C22–C26), whereas the
L-PBE would sequester preferentially long chain fatty acid
substrates (C16–C18). Thus, our data verify the hypothesis
of Kikuchi and co-workers (43) that long chain fatty acids are
the major substrates of rat liver peroxisomes with the corre-
sponding enzymes induced by the fibrate treatment. In con-
trast, the abundance of enzymes for -oxidation of very long
chain fatty acids is comparatively low in both the induced
and un-induced state. In this context, it is interesting that
PMP70 is the only ABC half-transporter with a high concen-
tration in rat liver and a quite high induction rate, arguing for
its involvement in transport of long chain fatty acids (C16–
C18) across the peroxisomal membrane (see Ref. 44 for
review). Until now, however, only its role in the transport of
bile acid metabolites and branched chain fatty acids has been
indicated (45), the pathways found to be down-regulated or
unresponsive to bezafibrate in this study. Thus, in summary,
fibrate treatment in rodents induced highly specific changes
in peroxisomal enzyme content and metabolism (Tables 3
and 4), supporting the view of a modifiable signal transduc-
tion of the PPAR receptor in response to different ligands,
potentially by ligand-dependent interaction with variable
cofactors.
The ACOX1 has been described as the rate-limiting
enzyme of -oxidation (46, 47). We found that its abundance
remained more or less stable upon bezafibrate treatment in
both immunoblot and iTRAQ data when calculated per per-
oxisomal protein amount. At a first glance, this observation
seems to contradict previous investigations, where ACOX1
was also augmented (48). However, in comparison to L-PBE
and 3-ketoacyl-CoA thiolase, ACOX1 induction rates were
generally found to be low when measured in isolated peroxi-
somes (9). Because bezafibrate-induced protein changes are
dose- as well as time-dependent (49), the moderate enzyme
induction observed in our study might be related to the dis-
tinct routes of bezafibrate application, normal food intake
here versus gastric intubation in other studies. Nevertheless,
the distinct induction pattern of ACOX1 compared with
other enzymes of the -oxidation pathway raises the ques-
tion of how the metabolic flux of fatty acid breakdown is
regulated. Primarily, the pronounced induction of the con-
secutive enzymes points toward a rapid conversion of the
downstream metabolites, preventing the organelle from
accumulation of 3-hydroxyacyl- or ketoacyl-CoA esters.
Indeed, Osumi et al. (50) reported an inhibition of rat
ACOX1 by 3-ketohexadecanoyl-CoA at a Ki of 0.47 M.
Because the Km value of the 3-ketoacyl-CoA thiolase is 1.9
M (51), high induction rates of the enzymes of the 2nd and
3rd step of peroxisomal -oxidation may prevent ACOX1
from product inhibition during phases of increased fatty acid
breakdown. These findings are in line with the observations
of Aoyama et al. (52) indicating that enhanced -oxidation
rates because of ACOX1 overexpression are confined to cell
lines with low ACOX1 content. Because rat liver peroxi-
somes contain relatively high concentrations of ACOX1
(53), a strong induction could lead to inhibitory concentra-
tions of -oxidation products reducing its enzymatic activ-
ity. Moreover, ACOX1 is also inhibited by acetyl-CoA (54).
One of the mechanisms competing with this inhibition could
be the induction of peroxisomal carnitine acetyl- as well as
acyltransferases supporting a rapid export of chain-short-
ened fatty acids to the mitochondria for their final metabo-
lization. In addition, the up-regulated fatty acid-binding
protein p14, which was localized to peroxisomes recently
(55), could bind, solubilize, and deliver these mobilized non-
esterified fatty acids to the peroxisomal membrane, where
they can be converted to their carnitine derivatives by carni-
tine octanoyltransferase. Extending this view, the supply and
availability of CoASH as another regulating factor should be
mentioned, because for every chain-shortening event
another coenzyme A is consumed. Peroxisomes house an
internal pool of CoASH, which cannot diffuse across the
organellar membrane (56, 57). Horie et al. (58) have found an
increase in free CoASH upon fibrate stimulation, whereas
acyl-bound CoA remained stable, concluding that the free
CoASH concentration is a positive regulating factor in the
enhancement of the peroxisomal fatty acid oxidation system.
As described by Hunt et al. (59), the peroxisomal acyl-CoA
thioester hydrolase Ib, up-regulated in our study, shows high
affinities to acetyl-CoA. The induction of this enzyme could
force the recruitment of free CoASH through the hydrolysis
of acetyl-CoA otherwise accumulating in the peroxisomal
matrix. In parallel to an internal mobilization of CoASH, the
up-regulated cytosolic thioesterases could provide addi-
tional coenzyme A to be imported into the organelle by a yet
uncharacterized transport system. Hence, our data support
the view that free CoASH could be a rate-limiting factor
during bezafibrate-induced -oxidation. In summary, the
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enhanced rates of -oxidation of palmitoyl-CoA upon beza-
fibrate treatment, from 16.98 to 45.45 milliunits/mg (Table
3), might not only be accounted for by a mere numerical
increase of peroxisomal enzymes but supposedly also by a
streamlined close control of the intraorganellar flux.
Potential Functions of Newly Identified Peroxisomal Pro-
teins—Among the newly identified peroxisomal proteins, a
number of dehydrogenases/reductases were found. Judged
from the number of peptide identifications one of the most
prominent is the acyl-CoA dehydrogenase family member
11. Similar peptide counts were only obtained for enzymes of
major peroxisomal pathways like the ACOX1 or the keto-
acyl-CoA thiolase. This potential acyl-CoA dehydrogenase
was also found by Kikuchi et al. (43) but has not yet been
verified by cloning and colocalization experiments. This
enzyme bears two functional domains, a phosphotransferase
as well as an acyl-CoA dehydrogenase domain that is dis-
tantly related to the mitochondrial medium chain acyl-CoA
dehydrogenases (27% identities in the acyl-CoA dehydro-
genase domain). Because peroxisomal acyl-CoA oxidases are
related to this protein family (60), it remains to be clarified
whether this enzyme acts as a dehydrogenase or whether it is
a fourth acyl-CoA oxidase, potentially broadening the sub-
strate spectrum of peroxisomal -oxidation.
In addition to metabolic enzymes we detected proteins with
more basic potential functions in peroxisome maintenance.
Molybdopterin cofactor sulfurases usually provide a sulfur
atom for the molybdopterin cofactor or other metallo-sulfur
clusters (61). Because xanthine oxidase, which is located to per-
oxisomes in rodents (62), is a molybdopterin cofactor-using
protein, the newly identifiedMosc domain containing protein 2
could be an essential enzyme for the transfer of a sulfur group to
this protein. Indeed, the disruption of a human sulfur transfer-
ase was reported to lead to xanthinuria (63). Interestingly, this
protein was recently annotated in SwissProt as a complex with
cytochrome b5 and cytochrome b5 reductase (O88994).
Because both proteins are consistently identified in peroxiso-
mal liver samples (19, 23, 43), it has to be speculated if this
complex is also formed in peroxisomes.
The existence of a peroxisomal protease has been pro-
posed for decades.We detected a trypsin-like serine protease
(MGC34695, Tysnd1) in addition to the peroxisomal Lon
protease (43), which extends the potential of the organelles
to degrade endogenous proteins. During submission of this
manuscript, Kurochkin and co-workers (64) identified and
characterized the mouse variant of this protein. By using
overexpression experiments, the authors could show that
Tysnd1 is involved in the controlled cleavage of peroxisomal
matrix proteins such as ACOX1, D-PBE, SCPX, and the 3-ke-
toacyl-CoA thiolase. The authors speculate that Tysnd1
could take part in enhancing -oxidation by facilitating the
formation of multiprotein complexes modulating the sec-
ondary structure of individual constituents through enzy-
matic cleavage of otherwise inhibiting subgroups. Support-
ing these findings Tysnd1 was up-regulated by a factor of 2
after a 3-week treatment with high doses of bezafibrate. In
our experiments, however, Tysnd1 proved not to be up-reg-
ulated using lower doses and a shorter time period. In addi-
tion, a characterization of the ACOX1 tertiary structure
using two-dimensional blue native-PAGE (65) revealed that
this key component of the -oxidation chain can only be
found as a complex consisting of both precursor and cleaved
subunits A–C. In contrast, complexes consisting only of
completely processed polypeptides seem not to be present in
peroxisomes (supplemental Fig. S2), which suggests a more
complex regulating mechanism. Interestingly, in humans
two isoforms of Tysnd1 can be found as GenBankTM splice
variants, one lacking the C-terminal SKL sequence. Because
we detected another trypsin-like protein sequence, which
lacks any peroxisomal targeting sequence (Table 4), the
existence of further proteases, existing as previously undis-
covered splice variants, cannot be excluded.
We have also identified a new peroxisomal membrane pro-
tein PMP52 with five predicted transmembrane domains in
TMHMM(NP_001013318) thatmay fulfill a task in the process
of peroxisome maintenance. So far, PMP52 has no apparent
functional domains, which would specify a relation to a known
protein family. However, overexpression of PMP52 in CHO
cells caused alterations in peroxisomenumber andmorphology
affecting the import competence of the whole peroxisomal
compartment. The PMP52-induced changes were similar to
characteristic morphological changes observed upon induced
degradation of the peroxisomal compartment in CHO cells.4
Thus, PMP52 could be involved in the control of the turnover of
peroxisomes. A PSI-Blast search disclosed a weak but signifi-
cant relationship to themammalian PMP24 (30% identity in the
aligned sequence), another peroxisomal membrane protein
with no assigned function (66). Concerning evolutionary con-
servation, both proteins exist in deuterostomia as well as fungi.
In contrast, in protostomia (arthropods) as well as plants only
PMP52-like sequences exist, whereas PMP24 seems to be aban-
doned, suggesting a functional overlap of both proteins.
Kikuchi and co-workers (43) first mentioned the acyl-
CoA-binding protein RiK1300014E15, now classified as
ACBD5, as a peroxisomal constituent. However, the authors
concluded that this peptide sequence is the precursor pro-
tein of the 10-kDa acyl-CoA-binding protein, which is acti-
vated by PPARs (67). In the meantime, a whole gene family of
proteins bearing an acyl-CoA binding domain (ACBD1–5)
has been sequenced. According to the Pfam-data base ACB
domains bind medium and long chain fatty acids with very
high affinities and thus may fulfill important functions in
peroxisomes to be investigated. We cloned two forms of
ACBD5 and confirmed peroxisomal localization for both by
coexpression experiments. Because we identified the protein
only in the integral membrane fraction, we searched for
potential membrane domains using the TMHMM software.
The prediction of a single transmembrane domain is in line
with studies of Arabidopsis thaliana acyl-CoA-binding pro-
teins, which are also membrane-associated proteins (68).
However, because only the acyl-CoA binding domain is evo-
lutionarily conserved between both phyla, these membrane
domains must have developed independently as functional
4 G. H. Lu¨ers, unpublished observations.
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analogues. Besides the acyl-CoA binding domain ranging
from amino acids 44–132 (PF00887), ACBD5 shows only
regions of low complexity impeding further functional spec-
ulations. Interestingly, overexpression of ACBD5.2 and
ACBD5.1 in CHO cells leads to an elongation of peroxi-
somes, which is similar to the appearance of peroxisomes
after arachidonic acid treatment in HepG2 cells (69). The
commonly accepted concept of nuclear control of peroxi-
some proliferation via PPAR was recently questioned by
Zhang and co-workers (70), who demonstrated peroxisome
proliferation in PPAR-null mice. Thus, ACBD5 may influ-
ence peroxisomal proliferation directly, potentially linking
the abundance of cellular acyl-CoA to the peroxisomal fis-
sion events.
In summary, the combination of diverse techniques ranging
from quantitativeMS to cloning and the expression of epitope-
tagged fusion proteins and to immunocytochemical analysis of
their localization lead to the identification of several new per-
oxisomal proteins besides the already known ones, thus adding
new pieces to the mosaic of the of rat liver peroxisomal pro-
teome. The potential integration of new proteins such as
PMP52 or ACBD5 into aspects of biogenesis and turnover of
the organelle could pave the way for further functional studies.
With the modulation of the -oxidation enzymes and related
proteins (acyl-CoA thioesterases) upon the treatment with
bezafibrate, new light was shed on the differential regulation of
peroxisomal -oxidation pathways. Thus, quantitative mass
spectrometry promises to be a valuable extension to established
biochemical and molecular techniques, able to add new func-
tional aspects to long investigated areas of research.
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